A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Analytical Pharmacology

Analytical Pharmacology Core Facility (APCF)
The Analytical Pharmacology Core facility (APCF) encourages and facilitiates collaborative research between basic scientists and clinicians by providing a wide range of analytical services that benefit both groups. The APCF conducts pharmacokinetic and pharmacodynamic studies for both chemotherapy clinical trials and peer-reviewed preclinical studies.
The primary services of the APCF are:
  • Assay development and analysis (LS/MS/MS, GC/MS, HPLC, and AAS) of chemotherapeutic agents and related compounds.
  • Study design and expert analysis of pharmacokinetic, pharmacodynamic, and metabolic data.
The facility’s services are available to both City of Hope and external researchers.

Research reported in this publication included work performed in the Analytical Pharmacology Core supported by the National Cancer Institute of the National Institutes of Health under award number P30CA33572. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.


Contact Us

Edward Newman, Ph.D.
626-256-HOPE (4673)
Timothy W. Synold, Pharm.D.
626-256-HOPE (4673)
City of Hope and Beckman Research Institute
1500 East Duarte Road
Duarte, CA  91010-3000
Shapiro Building
Room 1042
Phone: 626-256-HOPE (4673), ext. 62110
Fax: 626-301-8898

Using the Facility

Scheduling Equipment
To access the Analytical Pharmacology Core facility, investigators should contactTimothy Synoldto start the process.

Services and Equipment

Services currently offered by the Analytical Pharmacology Core facility:
  • Initial consultation on research projects
  • Study design and protocol review
  • Development, implementation, and validation of analytical methods.
  • Sample analysis (LC/MS/MS, GC/MS, HPLC, and AAS).
  • Pharmacokinetic programming and data analysis
  • Sample acquisition, tracking, and storage. Sample acquisition, storage analysis, including HPLC, LC/MS/MS and GC/MS, and microbiological assay methodologies
  • Participation in collaborative writing

Analytical capabilities cover a wide range of available methods including:
  • LC/MC/MS (Waters Quattro Ultima and Quattro Premier XE
  • GC/MS (2 Shimadzu QP-5000's
  • HPLC with UV/Vis, fluorescence, and electrochemical detection (Shimadzu and Thermo Separations)
  • AAS with graphite furnace (PerkinElmer AAnalyst 300

HPLC capability includes four complete systems, which are integrated directly to dedicated computers running EZChrom software for automated post-run analysis. Three of the HPLC systems include automated injection systems for more convenient analysis of a large number of samples.

Instrument control and data acquisition for the Micromass mass detector and the associated Agilent HPLC are coordinated through a MassLynx-NT workstation running MassLynx and QuanLynx software. The GC/MS instrumentation is composed of a Shimadzu Model QP-5000 EI gas chromatograph/mass spectrometer, interfaced directly to a dedicated computer running CLASS-5000 software.

In addition to the chromatographic instrumentation, a Perkin Elmer AAnalyst 300 flameless atomic absorption spectrometer (AA) is available for the determination of metals and metal-containing compounds such as cisplatin and its analogs. Sample analysis by AA utilizes an automated injection system, with data acquisition and analysis using WinLab software on a dedicated computer.


Abstract for Grants

The APCF is located in the Shapiro Building and the analytical equipment is in room 1042. Freezers for sample storage are also located in the Beckman Center Freezer Farm, Room 1012. An additional HPLC with a diode array detector that is used part time for core service activities is located in room 1002 of the Fox North Research Building. HPLC capability includes four complete HPLC systems consisting of seven solvent delivery modules (4 Shimadzu LC-10A's, 2 Shimadzu LC-10AD's, 1 SpectraSystem P4000). HPLC detection capabilities cover a wide range of currently available methods, including UV/Vis (Shimadzu SPD-10AV), fluorescence (Shimadzu RF-10A), electrochemical (ESA models 5100A and 5200A), and photodiode array (SpectraSystem UV6000LP) detection systems. The Shimadzu HPLC systems are integrated directly into one of two dedicated PC's running Shimadzu EZChrom software for automated post-run analysis. Likewise, the SpectraSystem system is integrated to a dedicated PC running Chromquest (OEM version of EZChrom software). Three of the four HPLC systems include automated injection systems (2 Shimadzu SIL-10A's, 1 SpectraSystem AS3000) for more convenient analysis of a large number of samples. A Perkin Elmer AAnalyst 300 AA is available for the determination of metals and metal containing compounds, such as cisplatin and its analogs. Sample analysis by AA utilizes an automated injection system, with data acquisition and analysis using WinLab software on a dedicated PC. The GC/MS instrumentation is composed of a Shimadzu Model QP-5000 EI gas chromatograph/mass spectrometer, interfaced directly to a dedicated PC running CLASS-5000 software. A Micromass Quattro Ultima API Triple Stage Quadrupole Mass Spectrometer System (LC/MS/MS) provides exquisite selectivity and sensitivity for analytes in complex biological matrices. Instrument control and data acquisition for the Micromass mass detector and the associated Agilent HPLC are coordinated through a MassLynx-NT Workstation running MassLynx and QuanLynx software. As a result of high demand for LC/MS/.MS services, a second triple quadrupole tandem mass spectrometer (Waters Premier XE) was recently obtained to increase our capabilities. The front-end on the Premier XE is a Waters Agility Ultra-high Pressure Liquid Chromatograph (UPLC) that allows us to maximize sensitivity and minimize run-times, thereby increasing throughput. Like the Quattro Ultima, instrument control and data analysis on the Premier XE is performed with MassLynx and QuanLynx software. In addition, MetaboLynx software was purchased to aid in metabolite identification.

Analytical Pharmacology Team

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
Media Inquiries/Social Media

For media inquiries contact:

Dominique Grignetti


For sponsorships inquiries please contact:

Stefanie Sprester

Christine Nassr

Facebook  Twitter  YouTube  Blog
  • For breast cancer survivors, a common worry is a recurrence of their cancer. Currently, these patients are screened with regular mammograms, but there’s no way to tell who is more likely to have a recurrence and who is fully cleared of her cancer. A new blood test – reported in Cancer Research, a journal of the...
  • Metastasis — the spreading of cancer cells from a primary tumor site to other parts of the body — generally leads to poorer outcomes for patients, so oncologists and researchers are constantly seeking new ways to detect and thwart this malicious process. Now City of Hope researchers may have identified a substa...
  • Deodorant, plastic bottles, grilled foods, artificial sweeteners, soy products … Do any of these products really cause cancer? With so many cancer myths and urban legends out there, why not ask the experts? They can debunk cancer myths while sharing cancer facts that matter, such as risk factors, preventi...
  • Cancer risk varies by ethnicity, as does the risk of cancer-related death. But the size of those differences can be surprising, highlighting the health disparities that exist among various ethnic groups in the United States. Both cancer incidence and death rates for men are highest among African-Americans, acco...
  • George Winston, known worldwide for his impressionistic, genre-defying music, considers music to be his first language, and admits he often stumbles over words – especially when he attempts languages other than English. There’s one German phrase he’s determined to perfect, however: danke schön. Winston thinks h...
  • Few decisions are more important than those involving health care, and few decisions can have such lasting impact, not only on oneself but on relatives and loved ones. Those choices, especially, should be made in advance – carefully, deliberately, free of pain and stress, and with much weighing of values and pr...
  • Using a card game to make decisions about health care, especially as those decisions relate to the end of life, would seem to be a poor idea. It isn’t. The GoWish Game makes those overwhelming, but all-important decisions not just easy, but natural. On each card of the 36-card deck is listed what seriously ill,...
  • Young adults and adolescents with cancer face unique challenges both during their treatment and afterward. Not only are therapies for children and older adults not always appropriate for them, they also must come to terms with the disease and treatment’s impact on their relationships, finances, school or ...
  • Breast cancer is the most common cancer, other than skin cancer, among women in the United States. It’s also the second-leading cause of cancer death, behind lung cancer. In the past several years, various task force recommendations and studies have questioned the benefits of broad screening guidelines fo...
  • Paternal age and the health effects it has on potential offspring have been the focus of many studies, but few have examined the effect parental age has on the risk of adult-onset hormone-related cancers (breast cancer, ovarian cancer and endometrial cancer). A team of City of Hope researchers, lead by Yani Lu,...
  • Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal h...
  • Myeloproliferative neoplasms can’t be narrowed down to a single cancer, but they can be described by a defining characteristic: too many blood cells. The diseases bring with them a host of frustrating, potentially life-altering symptoms, and management of the diseases and their symptoms is crucial. An upcoming ...
  • More than 18,000 researchers, clinicians, advocates and other professionals will convene at the 105th American Association for Cancer Research (AACR) annual meeting taking place in San Diego from April 5 to 9. With more than 6,000 findings being presented over this five-day period, the amount of information can...
  • Cancer of the prostate is the No. 2 cancer killer of men, behind lung cancer, accounting for more than 29,000 deaths annually in this country. But because prostate cancer advances slowly, good prostate health and early detection can make all the difference. Many prostate cancer tumors don’t require immedi...
  • Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer’s ability to resist treatment, renderi...